pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$AKBAAkebia Therapeutics, Inc.

$AKBA1.2900-2.27%
Cambridge, MA, USupdated 6d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
4
marketed
2
phase 3
0
catalysts ytd
2
approvals ytd
1
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 2: 1Marketed: 2Unknown: 1
1Phase 22Marketed1Unknown
Marketed
ferric citrate
Hyperphosphatemia In Chronic Kidney Disease
Marketed
vadadustat
Coronavirus Disease 2019 (COVID-19) Associated Acute Resp…
Egl nine homolog 1Prolyl hydroxylase EGLN2
Phase 2
praliciguat
Focal Segmental Glomerulosclerosis (FSGS)
Soluble guanylate cyclase
drug
VAFSEO
1 INDICATIONS AND USAGE VAFSEO is indicated for the treat…
Egl nine homolog 1Prolyl hydroxylase EGLN2

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)recruitingn=60
  • phase1SAD and MAD Study of AKB-9090 in Healthy Adult Participantsrecruitingn=70
  • phase3To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysisactive not recruitingn=353
  • phase3Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agentswithdrawn
  • phase3Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Diseasewithdrawn
  • phase3Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)completedn=319
  • phase3Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjectscompletedn=456

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 4, 26BUYButler John P.· CEO and President69,270 sh @ $1.25$87K↗
routine RSU / option mechanics (1)
  • Apr 1, 26grantVickers Philip J. · 214,400 sh
🐶 Hiring Signal
No open roles indexed yet — view Akebia Therapeutics, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$AKBA
SEC CIK
0001517022
country
US
source
sec_tickers
top tags
Infectious Disease1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 1m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?